Drospirenone and estradiol: a new option for the postmenopausal woman

References

• Greendale G A, Judd H L. The menopause: health implications and clinical management. J Am Geriatr Soc 1993; 41: 426–436
   PubMed Web of Science ®Google Scholar
• Warren M P, Halpert S. Hormone replacement therapy: controversies, pros and cons. Best Pract Res Clin Endocrinol Metab 2004; 18: 317–332
   PubMed Web of Science ®Google Scholar
• Rosano G M, Panina G. Oestrogens and the heart. Therapie 1999; 54: 381–385
   PubMed Web of Science ®Google Scholar
• Rossi R, Grimaldi T, Origliani G, Fantini G, Coppi F, Modena M G. Menopause and cardiovascular risk. Pathophysiol Haemost Thromb 2002; 32: 325–328
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E. Hormone replacement therapy and risk of malignancy. Curr Opin Obstet Gynecol 2004; 16: 73–78
   PubMed Web of Science ®Google Scholar
• Krieger N, Lowy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health 2005; 59: 740–748
   PubMed Web of Science ®Google Scholar
• de Lignieres B. Endometrial hyperplasia. Risks, recognition and the search for a safe hormone replacement regimen. J Reprod Med 1999; 44: 191–196
   PubMed Web of Science ®Google Scholar
• Anderson G L, Limacher M, Assaf A R, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer R D, Manson J E, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006; 166: 357–365
   PubMed Web of Science ®Google Scholar
• Phillips L S, Langer R D. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005; 83: 558–566
   PubMed Web of Science ®Google Scholar
• Salpeter S R, Walsh J M, Greyber E, Ormiston T M, Salpeter E E. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004; 19: 791–804
   PubMed Web of Science ®Google Scholar
• Muhn P, Fuhrmann U, Fritzemeier K H, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995; 761: 311–335
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Krattenmacher R, Slater E P, Fritzemeier K H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–251
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progesterone. Contraception 2000; 62: 29–38
   PubMed Web of Science ®Google Scholar
• Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung 1985; 35: 459–471
   PubMed Web of Science ®Google Scholar
• Pollow K, Juchem M, Elger W, Jacobi N, Hoffmann G, Mobus V. Dihydrospirorenone (ZK30595): a novel synthetic progesterone – characterization of binding to different receptor proteins. Contraception 1992; 46: 561–574
   PubMed Web of Science ®Google Scholar
• Archer D F, Thorneycroft I H, Foegh M, et al. Long-term safety of drospirenone–estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–727
   PubMed Web of Science ®Google Scholar
• Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin–aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–842
   PubMed Web of Science ®Google Scholar
• Oelkers W K. Effects of estrogens and progestogens on the renin–aldosterone system and blood pressure. Steroids 1996; 61: 166–171
   PubMed Web of Science ®Google Scholar
• Oelkers W, Helmerhorst F M, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin–angiotensin–aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–213
   PubMed Web of Science ®Google Scholar
• Foidart J M. Added benefits of drospirenone for compliance. Climacteric 2005; 8(Suppl 3)28–34
   PubMedGoogle Scholar
• Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7: 189–196
   PubMed Web of Science ®Google Scholar
• White W B, Pitt B, Preston R A, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112: 1979–1984
   PubMed Web of Science ®Google Scholar
• Preston R A, White W B, Pitt B, Bakris G, Norris P M, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18: 797–804
   PubMed Web of Science ®Google Scholar
• White W B, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48: 246–253
   PubMed Web of Science ®Google Scholar
• Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004; 7: 103–111
   PubMed Web of Science ®Google Scholar
• Stevenson J C. A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity. J Br Menopause Soc 2006; 12(Suppl 1)8–10
   PubMedGoogle Scholar